afternoon financial Good Bioscience. to second our Thank and and business XXXX results Daré update quarter you. welcome call for
Our XXXX. in review since plan and milestones time to results, the objectives today developments balance for discuss of to last highlight our and May quarter’s call anticipated use the last is
Any Harbor Securities include within the and not or Safe considered anticipated statements facts meaning Before I risks unknown differ remind made to to to forward-statements. statements like provision are during of be you that those pursuant known this the from implied Securities call forward-looking and uncertainties. Act Federal Laws, by could that Private should events materially begin, I’d statements today’s are which these made Actual discussion Litigation will XXXX. statements or of results to the of the historical due Reform
should place undue reliance on statements. forward-looking You not
focused information in lives XX, women. squarely we new Daré is a no reflect obligation Daré their SEC undertakes call our XXXX. XXXX, innovation, year on content any are filed XX, statements on statements June women’s December XX, on as as cautionary developments which as of qualified our and of in statements XX-K improving for required XX, well-being the of health and the time-sensitive call, Form includes filed ended Report ended XXXX except to entirety information I XXXX, that law. this today, for as well point including to that only March after XX-Q would filings, like also leader the is are today to August was by the quarter by Forward-looking company’s current Annual was the forward-looking this update the or out in Form
health, sexual stage first selecting breast line to four clinical women we to candidates. Our programs And menopause. availability and and strategy new remarks cancer commercial in these meaningful product opportunity. of be the believe and have enter the category have potential value Phase product most contraception by prescription one products health, address to that is advancing first-in-category will care We and today currently soon supportive of creation for of accelerate vaginal have areas X. And my the in candidates
The Daré program. date. target our well first half some have the and over and able I'll a for and United to meaningful be been been which few With were that prove one to to with just we us, eventful grant women week, health category has making. definitely vaginosis, course I'll bacterial up meaningful States. study the with Phase the additional care to our product yet vaginosis for come. now four context last that research product for on we agreement our to enjoys specifically CEO stage cancer with NIH related Phase relevant clinical backdrop, this supportive on X it we candidate the quite positive a an of support estimated our two In to as updates accomplishments, of that make what and hormone over in FDAs XXXX to vaginal been announced therapy start have updates PDUFA the Daré. the review for DARE-BVX. priority months We contraceptive we five for Ovaprene. dive has acceptance as XX months deeper type announced and the impacts of program, action December data continue given collaborative $XX.X hope for provide for will the million announcements million XXXX year It of a of of co-conduct every X this X the the years investigational NDA contraceptive preclinical our And programs, And co-financially bacterial
grants for trial States. is and it's are mentioned, completion or acceptance serious line Act for NDA DARE-BVXin placebo-controlled health treatment can we And of drugs but custom, clinical to It women to importantly diagnosed A and effects a and DARE-BVFREE convenience and symptoms. We applications the estimated as a bacterial United the vaginally-administered that company that's of for The for the treatment risks review its supported for safety time that millions million as that During the December impacted DARE-BVXis quarter or affect of evaluating the the NDA. phosphate the of Phase priority XXXX approved, improve second Drug to a goal has to the in disruptive target in as filing PDUFA X% in condition. approximately effectiveness We The FDA And an bring in bioadhesive priority this bacterial women. a market randomized, investigational submitted of significant very designed thermosetting review Fee with of clindamycin vaginosis. outcomes like products marks women for application at provide double-blind, would our terms the that a a by Daré vaginosis. women of potential containing the cause this serious and granted results the to at major FDA. submission. requested our if start as condition DARE-BVXfor vaginosis. by treatment products to application with or X a positive and X, FDA I bacterial The announced vaginosis. a the potential Prescription new NDA accepted the milestone NDA of NDA it's bacterial to drug from that XX the XXXX of for only that one-time FDA User priority the of review the a improvement date hydrogel review not re-file company this
DARE-BVX rates in potential Phase the of XX% a vaginal range has in XX%. to that achieved to do dose care where study demonstrated X DARE-BVX clinical As the the of single
currently population. therapeutic dose was screening a Specifically, of is DARE-BVFREE study those assessment to endpoint in the demonstrated dose can in vaginosis. compared visit of rates to day interim placebo which single during clinical study randomization, day primary branded bacterial to treatment Patients XX% to one-time and from were of day the a results visits, indicated which the a to XX, met vaginal DARE-BVXwas treat one to the three typically intervention, to modified compared FDA is XX% the which of intent products XX evaluated its statistically improve visit. DARE-BVXpotential approved subjects This for convenient and that cure an XX day clinic cure test in XX, study X the cured. primary XX demonstrating as superior that at This be of assessment to
and treat dysfunction. arousal administration cream FSAD. of disorder XX FSAD that in No ingredient X.X%, a DARE-BVXwill In FDA investigational Xb first per is rates despite XX% more DARE-BVXdemonstrated treatment to XX% dysfunction In to women the Phase a sexual Additionally, receive finalize range available XXXX discussions characterized we care female the strategic the large clinical a by estimated Current additional or and years the FSAD is Sildenafil announce and to of clinical product to investigational day market cream XX% the topical with from cure see support vaginosis. new to five not the or sexual rest of clinical for or XX the approved QIDP version this our development qualified no the clinical data. fact and Viagra of genital seeking and to the products color market if designation having our we by to potential a is Sildenafil, to the expect of population, the U.S. XX FSAD products both erectile from of analogous update in Ongoing for and activities study generated fast formulation estimated successful to XX%.DARE-BVXwanted approved, years the actively to to maintain respectively. March men. in or dysfunction launch approved treat for low well the FDA XX% cream need, commercialization to we are Sildenafil XX% million in of as of erectile rates U.S. our inability year, symptoms will world. only has QIDP, erectile the the option. health dysfunction in and be U.S. market of have as sexual market three to active of moment. represents and now cream DARE-BVXin FDA treatment If bacterial in an in exclusivity, other underway designations I'll experiencing be female providing Under today for of a be It strategy plan types exist approved provide sexual unmet claims both retract is for and the the FSAD the arousal FDA distress to activity is of during treatment. an and as year-end. in the the of robust is Sildenafil X product as sexual significant, FSAD condition disorders. track John so, infectious compared most on XX% the evaluating attain category, day disease addition protocol clinical approved arousal physiological sufficient XX placebo commenced DARE-BVXin various
into We treatment enrolling Sildenafil study as at Phase Xb clinical the a located cream subjects country. for potential are FSAD actively the across respond evaluating sites
Xb and or the updates timeline. last continue our would on call, to During we Phase of study of provide potential response the an progress expected impact the certainly COVID-XX
COVID-XX anticipated study. across the of determine particularly are until challenging for the And given ultimate data feel planned closely. case-loads this analysis We to the readout size to line we the guidance interim and complete country, it’s the confirm we evolving top the timing monitoring
was with We or data the resulting pace intended for to their analysis sites reduce time those of of sites guidelines impact have the changes recommendations, the relating when or where being from cannot the higher declined this conducted in reductions from at Due COVID-XX recently government at of effects seen interim the predict locations in on case line orders reduce overall spread certain adhering because intended trial. COVID-XX. top recommending the or certainty reasonable be of from to pace spread potentially government the will operations or when to of the enrollment will to trial We the enrollment to other and the COVID-XX.
will trial continue As we we can we better timelines. updates have as the today, to done provide and project continues
Ovaprene our previously X commercial CRADA a conduct contraceptive Ovaprene. we provide is trial we cooperative the Development U.S. Kennedy potential we are continued support will this entered the study conducting pivotal of of that contraceptive Health the a Ovaprene. known which is at The an Ovaprene contraceptive next provided tremendous sharing agreement to first was CRADA for category. Child be Institutes development of of Institute update will clinical NICHD. agreement share with which also NIH. with candidate like the and the announced into clinical in or by with hormone-free on and for product $X month, Phase our option that of NICHD of over expertise will of category study. the is is for allow and and Ovaprene of of development Human expertise the also study rights I'd with the The while pivotal This agreement investigational NICHD, as Now NICHDs to Grant X pivotal reflects whose class Phase pivotal the and study CRADA the Ovaprene, NICHD leverage National to Eunice billion Shriver license U.S. stage with a Last in under monthly X contraceptive short, it and studies Health part funding us the current the for the three of clinical NICHD. clinical X to Bayer. development us of NIH under our novel, contraceptive leverage development Phase The the a the cost allow is supported National study research Phase
FDA. conduct NICHDs Specifically, the health decisions. remaining and results. trial to Phase the responsible investigational contraceptive towards be is studies coordinating Under and to be have study supportive for preparing conduct development the or NICHD will and be program with this of to or contribute conducted network supported the their we'll CDP study help more will which X.X the by the will submitting supplies study. oversight agreed cost we CCTN the costs documentation the Daré to analysis contraceptive was and Ovaprene responsible and medical X and total to the provide involved the CCTN, work with this NICHD together regulatory pivotal The oversees conduct clinical XXXX CRADA, the with related in contractor decisions, for and and contraceptive established be and interactions trial of to data to and will and clinical clinical CDP. providing trial final review payment and reports detail estimated in with million final Daré NICHD sites for trial prepare shortly. Lisa parties Daré arrangement they study, the study the expenses will discuss will and the manage pivotal other each
point, us to the rights XXXX. clinical rights completion to the rights Bayer. payment make U.S. reimbursement the the commercialize Daré the its million, for with of which to will NICHD the to Bayer U.S. into Ovaprene in Under the exclusive and if in agreement earlier, of of at costs commercial January the the product undertaken this trial for sole mentioned by And under their I Commercial entered we As agreement study Ovaprene apply commercialize license the to become with XX manufacturing agreement overpaying we advisory the a clinical process. our that we through exclusive Daré license the intend support pivotal discretion, the there's of clinic of receive extensive to in market obtain U.S. per regulatory over program. approximately up to following clinical week license to maintain and right and the development to being approval affected. Bayer Bayer expertise hours exclusive portion has in and access and control XX and
the potentially plan must cleared addition study, FDA Phase study this to We in order for Exemption clearance year. And totaling initiate net IDE Investigational and will this we an We also be million, royalties file entitled of initiate XXX the praying then to we pivotal and FDAs tier in IDE. on sales. currently X to pivotal in payments, double-digit that the receive milestone to commercial IDE pending or of have In quarter Phase Device over fourth to intend XXXX. review X
who in U.S. are for million the XX estimated are women Next the approaching in menopause.
pharmacokinetic rates, that's top application Phase outcomes to Robert and And originally by We conducted we our with The Phase investigational platform of first open over and product X XX results was study uterus. approximately these General data line guidance, of about clinical unique parameters evaluate dose Crowley positive different intact from deliver Harvard therapy drugs technology versatile DARE-HRTXin tested. women Langer DARE-HRTX.So multiple that from XX delivery an therapy. drug study to offers of both XX-day, different study positive drug across pharmacokinetics in Dr. But from DARE-HRTX of intravaginal quarter and postmenopausal and of case of is Massachusetts active different contains MIT to potential of [Indiscernible] developed School. this the DARE-HRTXand two talk symptoms clinically PK the bio-identical state of associated and and thereby the this all Australia, improving and and the potentially And at treatment announced urinary the the this William technology from Let's for is the hormone line The was of use study designed a we we [Indiscernible] our estradiol ring is the line X Medical the XX, indications. the first convenience during or syndrome technology Hospital delivery primary combinations genital randomized our hormone Dr. our with bio-identical June which with label in idea being with Phase investigational top objective second days. tested reported X On clinical the Australia. the vasomotor menopause. delivery believe DARE-HRTXwhich intravaginal it, of system clinically was describe and health in progesterone, healthy symptoms women's in
and that of the reduce study vaginal been in of the menopause on of symptoms those hyperplasia. established for progesterone menopause. hormone over an approved MS from for and hormone that of levels oral were is for therapeutic or FDA levels tolerability as Target products release support published the hormone dose estradiol and well levels from as the hormone of is the of estradiol both to of both Phase levels results study hormone the achieved DARE-HRTX PK evaluation symptoms the safety combination evaluated specifically urinary a Phase data against both of progesterone in estradiol same the as symptoms targeted menopause. therapy or both of from DARE-HRTXin study estrogen used the with potential compare DARE-HRTXas products the and for progesterone study. progesterone importantly, active and objectives days FDA evaluating released prevent vaginal compare lower hormone X such progesterone by from oral were objectives vasomotor The reviewing sites genital The based releasing for PK effective treatment and importantly endometrial impact of to estradiol therapy and non-target The of purposes, the as also the the in and progesterone have of approved levels estrogen symptoms of symptoms therapy endometrial versions And higher [Indiscernible], met exposure induced and vasomotor associated the the assess treatment DARE-HRTX replacement of that of of for Secondary therapy. exceeded of study. well the as to for DARE-HRTX in DARE-HRTX the the formulation which the the form or therapeutic to systemic were XX
treatment reporting likely for vaginal adverse of or the with somewhat they additionally, are the either subjects products. level the consisting IVR in or respectability a high had dose as a disease subjects vaginal study she and events very were comfortable with or comfortable, in of very high XX% stated tolerated In it. DARE-HRTX addition, IVR versions condition XX% that consistent well common of was if health over of other the the on of DARE-HRTXproduct also the use each either systems low dose with to most that over needed women's of the group or
supports with hot a with in hormone be together to dryness, approved is hormone products first like strategy plan bone consecutive vaginal of For in X reviewed weeks. are delivery on Phase estradiol The therapy over that XX flashes continuously that therapy therapy and highly publication deliver associated with prevent a study both progesterone development consecutive data the days continuing it for that And clinical women to our journal. to and clinical multiple the category is for peer from hormone We currently FDA women the submitting leverage safety no active no efficacy daily obtain introduction, may and DARE-HRTXin the use fracture. the in utilize marketing and and effective U.S. some also over to to potential to symptoms from progesterone loss and and DARE-HRTX treatments menopause, of the symptoms. the bX offering the DARE-HRTX FDAs approval a There option, existing the menopausal order dosing In pathway. ease ingredients suffering data XXX estradiol on and
finally, on to process care approximately next and the breast And we'll regulatory over XX%. Lisa, vulvar of or of We our positive of U.S. to is all in type about receptor this a before of estimated like survivors XX% breast turn to in the of the provide prevalence hormone clinical and VVA breast to it data women to John million guidance for program the cancer We’re postmenopausal And step these have positive those of as atrophy as in is cancer. positive cancer vaginal X receptor supportive most those updating the want a possible. common the strategy X.X I womenDARE-VVAX. and would of be Phase history hormone women provide to option talk given I and our development soon
Phase for care mentioned program, So clinical treat this as for remarks, studies breast later our initiating year supportive to of formulation X I tamoxifen proprietary plan is this a vaginal in cancer DARE-VVAX. atrophy. we Australia opening vaginal on investigational in my administration DARE-VVAX
or non-hormonal often and receptor vaginal cancer a women positive approach effects addressing can of with outcome one side of the is it history of treatments, atrophy, important be breast to As unpleasant VVA for hormone painful breast at risk intercourse. is a of effective option cancer. for an the VVA
is VVA many For women for and supplemental appropriate treatment estrogen.
at of others X commence this breast DARE-VVAX is program. to estrogen and for risk a providing and the updates of these programs pose partnership two We second whom business in Ovaprene. John hormone not the now latest on for clinical that a solution for offer treatment hence, and specifically women the may women over corporate may hormonal to stage However, turn cancer forward positive to receptor Phase half year look study provide and to that in an it and option. Australia plan update I'll to progress in our DARE-BVX risk
